Compare Stocks: HCWB, ALVR, MDXH, and NEUP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVR AlloVir	$4.07 -2.9%	$4.31	$7.96 ▼ $24.15	$20.53M	0.63	15,685 shs	58,832 shs
HCWB HCW Biologics	$3.27 -4.1%	$5.28	$1.50 ▼ $44.10	$5.45M	2.32	73,907 shs	39,135 shs
MDXH MDxHealth	$0.45 -1.5%	$0.48	$0.40 ▼ $5.33	$22.82M	1.42	279,643 shs	174,965 shs
NEUP Neuphoria Therapeutics	$3.86 +1.0%	$3.99	$3.19 ▼ $21.40	$20.65M	0.75	450,662 shs	15,497 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVR AlloVir	0.00%	+15.95%	-9.35%	-19.88%	+52.43%
HCWB HCW Biologics	0.00%	+6.56%	-25.05%	+84.28%	-87.70%
MDXH MDxHealth	0.00%	+10.29%	-3.15%	-76.83%	-82.67%
NEUP Neuphoria Therapeutics	0.00%	-1.55%	+7.91%	-26.11%	-48.59%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVR AlloVir	$4.07 -2.9%	$4.31	$7.96 ▼ $24.15	$20.53M	0.63	15,685 shs	58,832 shs
HCWB HCW Biologics	$3.27 -4.1%	$5.28	$1.50 ▼ $44.10	$5.45M	2.32	73,907 shs	39,135 shs
MDXH MDxHealth	$0.45 -1.5%	$0.48	$0.40 ▼ $5.33	$22.82M	1.42	279,643 shs	174,965 shs
NEUP Neuphoria Therapeutics	$3.86 +1.0%	$3.99	$3.19 ▼ $21.40	$20.65M	0.75	450,662 shs	15,497 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVR AlloVir	0.00%	+15.95%	-9.35%	-19.88%	+52.43%
HCWB HCW Biologics	0.00%	+6.56%	-25.05%	+84.28%	-87.70%
MDXH MDxHealth	0.00%	+10.29%	-3.15%	-76.83%	-82.67%
NEUP Neuphoria Therapeutics	0.00%	-1.55%	+7.91%	-26.11%	-48.59%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVR AlloVir	0.00	N/A	N/A	N/A
HCWB HCW Biologics	2.00	Hold	$30.00	817.43% Upside
MDXH MDxHealth	2.40	Hold	$3.50	670.93% Upside
NEUP Neuphoria Therapeutics	2.00	Hold	$21.00	444.04% Upside

Current Analyst Ratings Breakdown

Latest HCWB, ALVR, MDXH, and NEUP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	HCWB HCW Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/1/2026	NEUP Neuphoria Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
5/28/2026	HCWB HCW Biologics	Maxim Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$12.00 ➝ $30.00
5/15/2026	NEUP Neuphoria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/14/2026	MDXH MDxHealth	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00 ➝ $1.50
5/14/2026	MDXH MDxHealth	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$9.00 ➝ $5.00
5/14/2026	MDXH MDxHealth	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
5/14/2026	MDXH MDxHealth	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$7.00 ➝ $4.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVR AlloVir	N/A	N/A	N/A	N/A	$29.35 per share	N/A
HCWB HCW Biologics	$50K	104.64	N/A	N/A	$5.06 per share	0.65
MDXH MDxHealth	$107.88M	0.21	N/A	N/A	($0.24) per share	-1.89
NEUP Neuphoria Therapeutics	$15.65M	1.33	$0.16 per share	24.51	$10.11 per share	0.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVR AlloVir	-$190.42M	-$20.23	N/A	N/A	N/A	N/A	-71.03%	-61.27%	N/A
HCWB HCW Biologics	-$7.96M	-$56.75	N/A	N/A	N/A	-34.73%	-486.87%	-29.19%	8/10/2026 (Estimated)
MDXH MDxHealth	-$33.52M	-$0.65	N/A	N/A	N/A	-29.90%	N/A	-22.51%	8/13/2026 (Estimated)
NEUP Neuphoria Therapeutics	-$370K	-$11.06	N/A	N/A	N/A	N/A	-76.93%	-54.76%	9/2/2026 (Estimated)

Latest HCWB, ALVR, MDXH, and NEUP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/2/2026	Q4 2026	NEUP Neuphoria Therapeutics	-$0.56	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	MDXH MDxHealth	-$0.1934	N/A	N/A	N/A	$26.14 million	N/A
8/10/2026	Q2 2026	HCWB HCW Biologics	-$1.98	N/A	N/A	N/A	$5.73 million	N/A
5/15/2026	Q3 2026	NEUP Neuphoria Therapeutics	-$0.56	-$0.09	+$0.47	-$0.09	N/A	N/A
5/14/2026	Q1 2026	HCWB HCW Biologics	-$2.64	$0.37	+$3.01	$2.22	$6.54 million	$6.54 million
5/14/2026	Q1 2026	MDXH MDxHealth	-$0.1447	-$0.19	-$0.0454	-$0.17	$30.89 million	$23.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVR AlloVir	N/A	N/A	N/A	N/A	N/A
HCWB HCW Biologics	N/A	N/A	N/A	N/A	N/A
MDXH MDxHealth	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVR AlloVir	N/A	86.78	86.78
HCWB HCW Biologics	N/A	0.09	0.09
MDXH MDxHealth	N/A	1.63	1.46
NEUP Neuphoria Therapeutics	N/A	14.31	14.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVR AlloVir	66.05%
HCWB HCW Biologics	2.96%
MDXH MDxHealth	N/A
NEUP Neuphoria Therapeutics	15.90%

Insider Ownership

Company	Insider Ownership
ALVR AlloVir	32.07%
HCWB HCW Biologics	9.10%
MDXH MDxHealth	1.70%
NEUP Neuphoria Therapeutics	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVR AlloVir	110	5.04 million	3.43 million	No Data
HCWB HCW Biologics	40	1.60 million	1.45 million	Not Optionable
MDXH MDxHealth	300	49.50 million	48.66 million	Not Optionable
NEUP Neuphoria Therapeutics	N/A	5.40 million	5.32 million	N/A

HCWB, ALVR, MDXH, and NEUP Headlines

Recent News About These Companies

Neuphoria Therapeutics Inc (NEUP)

August 8 at 10:33 PM | investing.com

The M&A Class Action Firm Encourages $hareholders To Contact Monteverde Concerning The Merger—NRIM, NEUP, SAFT, and RMAX

July 30, 2026 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—PBCO, NEUP, SAFT, and PFLC

July 28, 2026 | globenewswire.com

NEUP Stock Alert: Halper Sadeh LLC is Investigating Whether Neuphoria Therapeutics Inc. is Obtaining a Fair Price for its Shareholders

July 24, 2026 | businesswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Neuphoria Therapeutics, Inc. (NASDAQ: NEUP)

July 24, 2026 | prnewswire.com

Small cap movers: Scancell heads to Nasdaq as AIM's headcount falls to 612

July 24, 2026 | msn.com

Scancell to go public after winning reverse merger bid for troubled Neuphoria

July 24, 2026 | fiercebiotech.comF

Scancell and Neuphoria agree all-share merger supported by up to US$89 million financing

July 24, 2026 | uk.finance.yahoo.com

Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing

July 23, 2026 | globenewswire.com

Neuphoria Therapeutics Stock Dividends | NASDAQ:NEUP | Benzinga

July 11, 2026 | benzinga.com

Merck axes Alzheimer’s study, adding to partner Neuphoria’s mounting woes

July 3, 2026 | biospace.comB

Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms

July 1, 2026 | fiercebiotech.comF

MRK, NEUP stocks drop as Merck scraps another Alzheimer’s drug trial under Neuphoria partnership

July 1, 2026 | msn.com

Neuphoria Therapeutics Inc. Common Stock

June 27, 2026 | fxempire.comF

Neuphoria Therapeutics in Talks to Be Acquired by Scancell Holdings

June 27, 2026 | marketwatch.com

Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc

June 26, 2026 | globenewswire.com

HC Wainwright & Co. downgrades Neuphoria Therapeutics (NEUP)

May 17, 2026 | msn.com

Neuphoria Therapeutics (NEUP) price target increased by 38.22% to 13.77

May 14, 2026 | msn.com

Here's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation

February 19, 2026 | uk.finance.yahoo.com

Neuphoria Therapeutics (NEUP) price target decreased by 32.33% to 9.96

December 22, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB, ALVR, MDXH, and NEUP Company Descriptions

AlloVir NASDAQ:ALVR

$4.07 -0.12 (-2.86%)

As of 08/7/2026

AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.

HCW Biologics NASDAQ:HCWB

$3.27 -0.14 (-4.11%)

As of 04:00 PM Eastern

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

MDxHealth NASDAQ:MDXH

$0.45 -0.01 (-1.52%)

As of 04:00 PM Eastern

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. The company offers genomic prostate score which provides personalized genomic insights to both physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. It sells its products through urology sales force, consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.

Neuphoria Therapeutics NASDAQ:NEUP

$3.86 +0.04 (+1.05%)

As of 04:00 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HCWB, ALVR, MDXH, and NEUP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HCWB, ALVR, MDXH, and NEUP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HCWB, ALVR, MDXH, and NEUP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB, ALVR, MDXH, and NEUP Company Descriptions

AlloVir NASDAQ:ALVR

HCW Biologics NASDAQ:HCWB

MDxHealth NASDAQ:MDXH

Neuphoria Therapeutics NASDAQ:NEUP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HCWB, ALVR, MDXH, and NEUP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HCWB, ALVR, MDXH, and NEUP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HCWB, ALVR, MDXH, and NEUP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCWB, ALVR, MDXH, and NEUP Company Descriptions

AlloVir NASDAQ:ALVR

HCW Biologics NASDAQ:HCWB

MDxHealth NASDAQ:MDXH

Neuphoria Therapeutics NASDAQ:NEUP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools